Comparisons of NAD Precursors for Neuroenhancement in Glaucoma Patients
NCT ID: NCT06991712
Last Updated: 2025-06-26
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
RECRUITING
Clinical Phase
PHASE2
Total Enrollment
138 participants
Study Classification
INTERVENTIONAL
Study Start Date
2025-05-19
Study Completion Date
2026-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The goal of this clinical trial is to determine whether oral supplementation with different nicotinamide adenine dinucleotide (NAD) precursors can improve visual function in adults with primary open-angle glaucoma. The main questions it aims to answer are:
1. Does daily oral administration of equimolar doses of nicotinamide riboside (NR), nicotinamide (NAM), nicotinamide mononucleotide (NMN), or nicotinic acid (NA) improve visual field sensitivity in glaucoma patients over the short term?
2. How do plasma NAD+ metabolite profiles change after administration of each precursor, and do these changes relate to improvements in visual function?
Researchers will compare NR, NAM, NMN, NA, and placebo groups to see if any of the NAD precursors lead to greater improvements in visual field sensitivity or changes in blood NAD+ metabolite levels compared to placebo.
Participants will:
Be randomly assigned to receive one of the four NAD precursors or placebo daily for two weeks.
Undergo comprehensive eye examinations, including visual field testing and optical coherence tomography, at baseline and after two weeks.
Provide blood samples before and after the intervention for measurement of NAD+ metabolites.
Have safety monitored through clinical examination.
This study will help identify whether boosting NAD+ levels with specific precursors offers functional benefit in glaucoma, and which blood metabolites may mediate these effects.
1. Does daily oral administration of equimolar doses of nicotinamide riboside (NR), nicotinamide (NAM), nicotinamide mononucleotide (NMN), or nicotinic acid (NA) improve visual field sensitivity in glaucoma patients over the short term?
2. How do plasma NAD+ metabolite profiles change after administration of each precursor, and do these changes relate to improvements in visual function?
Researchers will compare NR, NAM, NMN, NA, and placebo groups to see if any of the NAD precursors lead to greater improvements in visual field sensitivity or changes in blood NAD+ metabolite levels compared to placebo.
Participants will:
Be randomly assigned to receive one of the four NAD precursors or placebo daily for two weeks.
Undergo comprehensive eye examinations, including visual field testing and optical coherence tomography, at baseline and after two weeks.
Provide blood samples before and after the intervention for measurement of NAD+ metabolites.
Have safety monitored through clinical examination.
This study will help identify whether boosting NAD+ levels with specific precursors offers functional benefit in glaucoma, and which blood metabolites may mediate these effects.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Nicotinamide and Glaucoma
NCT05916066
Glaucoma
COMPLETED
NA
Nicotinamide and Pyruvate for Open Angle Glaucoma: A Randomized Clinical Study
NCT05695027
Primary Open Angle Glaucoma
ACTIVE_NOT_RECRUITING
PHASE2/PHASE3
Vision Preservation and Restoration Following a 6 Month Trial of GlaucoCetin
NCT04784234
Primary Open Angle Glaucoma
TERMINATED
NA
Efficacy of Nicotinamide on Retinal Ganglion Cell Functions in Glaucoma Patients
NCT06078605
Glaucoma
UNKNOWN
NA
Nicotinamide Levels in Serum, Aqueous Humor, and Tear Film in Glaucoma and Correlations With Mitochondrial Damage-Associated Molecular Patterns (mtDAMPs) and Senescence-Associated Secretory Phenotype (SASP)
NCT07006194
Glaucoma
NOT_YET_RECRUITING
NA
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This prospective randomized, double-blind, placebo-controlled clinical trial evaluates four nicotinamide adenine dinucleotide (NAD) precursors for neuroenhancement in 138 adults with primary open-angle glaucoma. Participants are randomly assigned to receive daily oral supplementation for one week with equimolar doses of nicotinamide riboside (300 mg), nicotinamide (125 mg), nicotinamide mononucleotide (350 mg), nicotinic acid (125 mg), or placebo. The study assesses short-term changes in visual field sensitivity using Humphrey Field Analyzer 24-2 testing and measures NAD+ metabolite profiles through liquid chromatography-tandem mass spectrometry (LC-MS/MS) and gas chromatography-tandem mass spectrometry (GC-MS/MS) analysis of plasma and peripheral blood mononuclear cells collected at baseline, pre-dose, and post-dose timepoints.
Secondary objectives include comparing pattern electroretinogram nerve fiber layer thickness measurements before and after treatment and analyzing correlations between systemic NAD+ metabolite elevations and functional visual improvements. Blood samples undergo standardized processing with Lymphoprep separation, snap-freezing, and derivatization protocols prior to mass spectrometry analysis using Agilent and Thermo Fisher systems with predefined NAD+ metabolite inclusion lists.
Statistical analysis employs linear mixed models to compare within-group and between-group changes, with intention-to-treat principles. The study design addresses gaps in comparative NAD precursor bioavailability data by testing equimolar doses in a targeted glaucoma population, while maintaining double-blinding through computer-generated randomization and masked outcome assessment.
Secondary objectives include comparing pattern electroretinogram nerve fiber layer thickness measurements before and after treatment and analyzing correlations between systemic NAD+ metabolite elevations and functional visual improvements. Blood samples undergo standardized processing with Lymphoprep separation, snap-freezing, and derivatization protocols prior to mass spectrometry analysis using Agilent and Thermo Fisher systems with predefined NAD+ metabolite inclusion lists.
Statistical analysis employs linear mixed models to compare within-group and between-group changes, with intention-to-treat principles. The study design addresses gaps in comparative NAD precursor bioavailability data by testing equimolar doses in a targeted glaucoma population, while maintaining double-blinding through computer-generated randomization and masked outcome assessment.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Glaucoma
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
NR, NAM, NMN, or NA in mole equivalent amount, or placebo, will be randomly assigned to 138 patients, 23 per group (a total of 4 treatment groups and 2 placebo groups). Each patient will receive a daily dose of 300 mg NR, 125 mg NAM, 350 mg NMN, 125 mg NA or 300 mg placebo (corn starch capsule) at 9 am each day for two weeks. The study will be conducted in 2 phases. In Phase I, participants will be randomized to placebo, NR, or NAM. In Phase II, participants will be randomized to receive, placebo, NA, or NMN.
Primary Study Purpose
TREATMENT
Blinding Strategy
QUADRUPLE
Participants
Caregivers
Investigators
Outcome Assessors
The participants, investigators, the outcome assessors, and data analysts will be masked before and after assignment to intervention.
The subject will be unmasked as per of the request of Principal Investigator in case of serious adverse event or if emergency unblinding is deemed essential for clinical management. All instances of the unblinding will be documented in the study binder. Unmasked subject will exit from the study and resumes normal clinical management.
The subject will be unmasked as per of the request of Principal Investigator in case of serious adverse event or if emergency unblinding is deemed essential for clinical management. All instances of the unblinding will be documented in the study binder. Unmasked subject will exit from the study and resumes normal clinical management.
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Nicotinamide Riboside (Phase I)
Group Type
EXPERIMENTAL
Nicotinamide Riboside
Intervention Type
DIETARY_SUPPLEMENT
Oral supplementation of 300mg Nicotinamide Riboside (NR) daily for 2 weeks
Nicotinamide (Phase I)
Group Type
ACTIVE_COMPARATOR
Nicotinamide
Intervention Type
DIETARY_SUPPLEMENT
Oral supplementation of 125mg Nicotinamide/Niacinamide (NAM) daily for 2 weeks
Nicotinamide Mononucleotide (Phase II)
Group Type
ACTIVE_COMPARATOR
Nicotinamide Mononucleotide
Intervention Type
DIETARY_SUPPLEMENT
Oral supplementation of 350mg Nicotinamide Mononucleotide (NMN) daily for 2 weeks
Nicotinic Acid (Phase II)
Group Type
ACTIVE_COMPARATOR
Nicotinic Acid
Intervention Type
DIETARY_SUPPLEMENT
Oral supplementation of 350mg Nicotinic Acid (NA) daily for 2 weeks
Placebo (Phase I)
Group Type
PLACEBO_COMPARATOR
Placebo (Corn Starch)
Intervention Type
OTHER
Oral supplementation of 300mg Placebo daily for 2 weeks
Placebo (Phase II)
Group Type
PLACEBO_COMPARATOR
Placebo (Corn Starch)
Intervention Type
OTHER
Oral supplementation of 300mg Placebo daily for 2 weeks
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Nicotinamide Riboside
Oral supplementation of 300mg Nicotinamide Riboside (NR) daily for 2 weeks
Intervention Type
DIETARY_SUPPLEMENT
Nicotinamide
Oral supplementation of 125mg Nicotinamide/Niacinamide (NAM) daily for 2 weeks
Intervention Type
DIETARY_SUPPLEMENT
Nicotinamide Mononucleotide
Oral supplementation of 350mg Nicotinamide Mononucleotide (NMN) daily for 2 weeks
Intervention Type
DIETARY_SUPPLEMENT
Nicotinic Acid
Oral supplementation of 350mg Nicotinic Acid (NA) daily for 2 weeks
Intervention Type
DIETARY_SUPPLEMENT
Placebo (Corn Starch)
Oral supplementation of 300mg Placebo daily for 2 weeks
Intervention Type
OTHER
Placebo (Corn Starch)
Oral supplementation of 300mg Placebo daily for 2 weeks
Intervention Type
OTHER
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
NR
Niacinamide
NAM
NMN
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* glaucoma patients
* age ≥ 18 years
* best corrected VA ≥20/40
* IOP \<21 mmHg
* visual field mean deviation better than -24 dB on standard automated perimetry 24-2 SITA standard
* age ≥ 18 years
* best corrected VA ≥20/40
* IOP \<21 mmHg
* visual field mean deviation better than -24 dB on standard automated perimetry 24-2 SITA standard
Exclusion Criteria
* pathological myopia
* diseases that may cause visual field loss or optic disc abnormalities other than glaucoma
* inability to perform reliable visual field
* suboptimal quality of OCT images
* diabetic retinopathy/maculopathy
* history of abnormal liver function within 12 months
* known allergy to NAD precursor supplement(s)
* pregnancy or lactation
* use of NAD precursor supplements 14 days prior to baseline.
* diseases that may cause visual field loss or optic disc abnormalities other than glaucoma
* inability to perform reliable visual field
* suboptimal quality of OCT images
* diabetic retinopathy/maculopathy
* history of abnormal liver function within 12 months
* known allergy to NAD precursor supplement(s)
* pregnancy or lactation
* use of NAD precursor supplements 14 days prior to baseline.
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Christopher Kai Shun Leung
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Christopher Kai Shun Leung
Chairperson and Clinical Professor
Responsibility Role
SPONSOR_INVESTIGATOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Christopher Kai-shun LEUNG, MD
Role: PRINCIPAL_INVESTIGATOR
The University of Hong Kong
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
HKU Eye Centre
Wong Chuk Hang, , Hong Kong
Site Status
RECRUITING
Countries
Review the countries where the study has at least one active or historical site.
Hong Kong
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Allison K, Patel D, Alabi O. Epidemiology of Glaucoma: The Past, Present, and Predictions for the Future. Cureus. 2020 Nov 24;12(11):e11686. doi: 10.7759/cureus.11686.
Reference Type
BACKGROUND
Bengtsson B, Lindgren A, Heijl A, Lindgren G, Asman P, Patella M. Perimetric probability maps to separate change caused by glaucoma from that caused by cataract. Acta Ophthalmol Scand. 1997 Apr;75(2):184-8. doi: 10.1111/j.1600-0420.1997.tb00121.x.
Reference Type
BACKGROUND
Bledi Petriti, Alessandro Rabiolo, Pete Williams, Kai-Yin Chau, Gerassimos Lascaratos, David F Garway-Heath; Primary open angle glaucoma patients have lower systemic mitochondrial function, associated with lower systemic nicotinamide adenine dinucleotide (NAD) levels, compared to Controls. Invest. Ophthalmol. Vis. Sci. 2023;64(8):483.
Reference Type
BACKGROUND
Bledi Petriti, Gerassimos Lascaratos, David Chau, Williams Peter, David F Garway-Heath; Preliminary data show Normal Tension Glaucoma patients have lower systemic nicotinamide adenine dinucleotide (NAD+) levels and mitochondrial function compared to Controls. Invest. Ophthalmol. Vis. Sci. 2021;62(8):1765.
Reference Type
BACKGROUND
Capuzzi DM, Guyton JR, Morgan JM, Goldberg AC, Kreisberg RA, Brusco OA, Brody J. Efficacy and safety of an extended-release niacin (Niaspan): a long-term study. Am J Cardiol. 1998 Dec 17;82(12A):74U-81U; discussion 85U-86U. doi: 10.1016/s0002-9149(98)00731-0.
Reference Type
BACKGROUND
Christopher Kai-Shun Leung, Philip Guo, Marco Yu, Gilda Lai; Nicotinamide Riboside for Progressing Glaucoma: A Double-blind, Parallel Group, Randomized, Placebo-controlled Trial - A Report on Neuroenhancement. Invest. Ophthalmol. Vis. Sci. 2023;64(8):4349.
Reference Type
BACKGROUND
Cros C, Cannelle H, Laganier L, Grozio A, Canault M. Safety evaluation after acute and sub-chronic oral administration of high purity nicotinamide mononucleotide (NMN-C(R)) in Sprague-Dawley rats. Food Chem Toxicol. 2021 Apr;150:112060. doi: 10.1016/j.fct.2021.112060. Epub 2021 Feb 12.
Reference Type
BACKGROUND
De Moraes CG, John SWM, Williams PA, Blumberg DM, Cioffi GA, Liebmann JM. Nicotinamide and Pyruvate for Neuroenhancement in Open-Angle Glaucoma: A Phase 2 Randomized Clinical Trial. JAMA Ophthalmol. 2022 Jan 1;140(1):11-18. doi: 10.1001/jamaophthalmol.2021.4576.
Reference Type
BACKGROUND
European Food Safety Authority. Tolerable Upper Intake Levels for Vitamins and Minerals (2006). Parma, Italy: European Food Safety Authority; 2006.
Reference Type
BACKGROUND
Medeiros FA, Zangwill LM, Bowd C, Mansouri K, Weinreb RN. The structure and function relationship in glaucoma: implications for detection of progression and measurement of rates of change. Invest Ophthalmol Vis Sci. 2012 Oct 5;53(11):6939-46. doi: 10.1167/iovs.12-10345.
Reference Type
BACKGROUND
Gardiner SK, Crabb DP. Frequency of testing for detecting visual field progression. Br J Ophthalmol. 2002 May;86(5):560-4. doi: 10.1136/bjo.86.5.560.
Reference Type
BACKGROUND
Garway-Heath DF, Crabb DP, Bunce C, Lascaratos G, Amalfitano F, Anand N, Azuara-Blanco A, Bourne RR, Broadway DC, Cunliffe IA, Diamond JP, Fraser SG, Ho TA, Martin KR, McNaught AI, Negi A, Patel K, Russell RA, Shah A, Spry PG, Suzuki K, White ET, Wormald RP, Xing W, Zeyen TG. Latanoprost for open-angle glaucoma (UKGTS): a randomised, multicentre, placebo-controlled trial. Lancet. 2015 Apr 4;385(9975):1295-304. doi: 10.1016/S0140-6736(14)62111-5. Epub 2014 Dec 19.
Reference Type
BACKGROUND
GRAS No 635, available at https://www.accessdata.fda.gov/scripts/fdcc/index.cfm?set=GRASNotices&id=635
Reference Type
BACKGROUND
Gupta D, Chen PP. Glaucoma. Am Fam Physician. 2016 Apr 15;93(8):668-74.
Reference Type
BACKGROUND
Harwerth RS, Carter-Dawson L, Shen F, Smith EL 3rd, Crawford ML. Ganglion cell losses underlying visual field defects from experimental glaucoma. Invest Ophthalmol Vis Sci. 1999 Sep;40(10):2242-50.
Reference Type
BACKGROUND
Heijl A, Bengtsson B, Hyman L, Leske MC; Early Manifest Glaucoma Trial Group. Natural history of open-angle glaucoma. Ophthalmology. 2009 Dec;116(12):2271-6. doi: 10.1016/j.ophtha.2009.06.042. Epub 2009 Oct 24.
Reference Type
BACKGROUND
Hui F, Tang J, Williams PA, McGuinness MB, Hadoux X, Casson RJ, Coote M, Trounce IA, Martin KR, van Wijngaarden P, Crowston JG. Improvement in inner retinal function in glaucoma with nicotinamide (vitamin B3) supplementation: A crossover randomized clinical trial. Clin Exp Ophthalmol. 2020 Sep;48(7):903-914. doi: 10.1111/ceo.13818. Epub 2020 Jul 28.
Reference Type
BACKGROUND
Institute of Medicine (IOM, 1998). Niacin: In: Dietary Reference Intakes for Thiamin, Riboflavin, Niacin, Vitamin B(6), Folate, Vitamin B(12), Pantothenic Acid, Biotin, and Choline. (National Academy of Sciences/NAS, Institute of Medicine/IOM, Food and Nutrition Board/FNB, Standing Committee on the Scientific Evaluation of Dietary Reference Intakes and its Panel on Folate, Other B Vitamins, and Choline, and the Subcommittee on Upper Reference Levels of Nutrients). Washington (DC): National Academy Press (NAP), pp. 123-149. Available at:http://www.nap.edu/openbook.php?record_id=6015&page=123
Reference Type
BACKGROUND
Ito, T. K., Sato, T., Hakamata, A., Onoda, Y., Sato, S., Yamazaki, F., Horikawa, M., Takahashi, Y., Kitamoto, T., Suzuki, M., Uchida, S., Odagiri, K., & Setou, M. (2020). A nonrandomized study of single oral supplementation within the daily tolerable upper level of nicotinamide affects blood nicotinamide and NAD+ levels in healthy subjects. Translational Medicine of Aging, 4, 45-54. https://doi.org/10.1016/j.tma.2020.04.002
Reference Type
BACKGROUND
Ito, Takashi & Sato, Tomohito & Takanashi, Yusuke & Tamannaa, Zinat & Kitamoto, Takuya & Odagiri, Keiichi & Setou, Mitsutoshi. (2021). A single oral supplementation of nicotinamide within the daily tolerable upper level increases blood NAD+ levels in healthy subjects. Translational Medicine of Aging. 5. 10.1016/j.tma.2021.09.001.
Reference Type
BACKGROUND
Jadeja RN, Thounaojam MC, Bartoli M, Martin PM. Implications of NAD+ Metabolism in the Aging Retina and Retinal Degeneration. Oxid Med Cell Longev. 2020 May 9;2020:2692794. doi: 10.1155/2020/2692794. eCollection 2020.
Reference Type
BACKGROUND
Kamanna VS, Ganji SH, Kashyap ML. The mechanism and mitigation of niacin-induced flushing. Int J Clin Pract. 2009 Sep;63(9):1369-77. doi: 10.1111/j.1742-1241.2009.02099.x.
Reference Type
BACKGROUND
Lautrup S, Sinclair DA, Mattson MP, Fang EF. NAD+ in Brain Aging and Neurodegenerative Disorders. Cell Metab. 2019 Oct 1;30(4):630-655. doi: 10.1016/j.cmet.2019.09.001.
Reference Type
BACKGROUND
Leung CKS, Ye C, Weinreb RN, Yu M, Lai G, Lam DS. Impact of age-related change of retinal nerve fiber layer and macular thicknesses on evaluation of glaucoma progression. Ophthalmology. 2013 Dec;120(12):2485-2492. doi: 10.1016/j.ophtha.2013.07.021. Epub 2013 Aug 30.
Reference Type
BACKGROUND
Lin C, Mak H, Yu M, Leung CK. Trend-Based Progression Analysis for Examination of the Topography of Rates of Retinal Nerve Fiber Layer Thinning in Glaucoma. JAMA Ophthalmol. 2017 Mar 1;135(3):189-195. doi: 10.1001/jamaophthalmol.2016.5111.
Reference Type
BACKGROUND
Lin JB, Kubota S, Ban N, Yoshida M, Santeford A, Sene A, Nakamura R, Zapata N, Kubota M, Tsubota K, Yoshino J, Imai SI, Apte RS. NAMPT-Mediated NAD(+) Biosynthesis Is Essential for Vision In Mice. Cell Rep. 2016 Sep 27;17(1):69-85. doi: 10.1016/j.celrep.2016.08.073.
Reference Type
BACKGROUND
Mahmoudinezhad G, Moghimi S, Proudfoot JA, Brye N, Nishida T, Yarmohammadi A, Kamalipour A, Zangwill LM, Weinreb RN. Effect of Testing Frequency on the Time to Detect Glaucoma Progression With Optical Coherence Tomography (OCT) and OCT Angiography. Am J Ophthalmol. 2023 Jan;245:184-192. doi: 10.1016/j.ajo.2022.08.030. Epub 2022 Sep 10.
Reference Type
BACKGROUND
Mehmel M, Jovanovic N, Spitz U. Nicotinamide Riboside-The Current State of Research and Therapeutic Uses. Nutrients. 2020 May 31;12(6):1616. doi: 10.3390/nu12061616.
Reference Type
BACKGROUND
Meyers CD, Carr MC, Park S, Brunzell JD. Varying cost and free nicotinic acid content in over-the-counter niacin preparations for dyslipidemia. Ann Intern Med. 2003 Dec 16;139(12):996-1002. doi: 10.7326/0003-4819-139-12-200312160-00009.
Reference Type
BACKGROUND
Morgan JM, Capuzzi DM, Guyton JR. A new extended-release niacin (Niaspan): efficacy, tolerability, and safety in hypercholesterolemic patients. Am J Cardiol. 1998 Dec 17;82(12A):29U-34U; discussion 39U-41U. doi: 10.1016/s0002-9149(98)00732-2.
Reference Type
BACKGROUND
Nouri-Mahdavi K, Nassiri N, Giangiacomo A, Caprioli J. Detection of visual field progression in glaucoma with standard achromatic perimetry: a review and practical implications. Graefes Arch Clin Exp Ophthalmol. 2011 Nov;249(11):1593-616. doi: 10.1007/s00417-011-1787-5. Epub 2011 Aug 26.
Reference Type
BACKGROUND
Norquist JM, Watson DJ, Yu Q, Paolini JF, McQuarrie K, Santanello NC. Validation of a questionnaire to assess niacin-induced cutaneous flushing. Curr Med Res Opin. 2007 Jul;23(7):1549-60. doi: 10.1185/030079907x199637.
Reference Type
BACKGROUND
Nouri-Mahdavi K, Hoffman D, Gaasterland D, Caprioli J. Prediction of visual field progression in glaucoma. Invest Ophthalmol Vis Sci. 2004 Dec;45(12):4346-51. doi: 10.1167/iovs.04-0204.
Reference Type
BACKGROUND
Okabe K, Yaku K, Uchida Y, Fukamizu Y, Sato T, Sakurai T, Tobe K, Nakagawa T. Oral Administration of Nicotinamide Mononucleotide Is Safe and Efficiently Increases Blood Nicotinamide Adenine Dinucleotide Levels in Healthy Subjects. Front Nutr. 2022 Apr 11;9:868640. doi: 10.3389/fnut.2022.868640. eCollection 2022.
Reference Type
BACKGROUND
Pardue MT, Allen RS. Neuroprotective strategies for retinal disease. Prog Retin Eye Res. 2018 Jul;65:50-76. doi: 10.1016/j.preteyeres.2018.02.002. Epub 2018 Feb 23.
Reference Type
BACKGROUND
Paolini JF, Mitchel YB, Reyes R, Thompson-Bell S, Yu Q, Lai E, Watson DJ, Norquist JM, Sisk CM, Bays HE. Measuring flushing symptoms with extended-release niacin using the flushing symptom questionnaire: results from a randomised placebo-controlled clinical trial. Int J Clin Pract. 2008 Jun;62(6):896-904. doi: 10.1111/j.1742-1241.2008.01739.x. Epub 2008 Apr 10.
Reference Type
BACKGROUND
Petriti B, Williams PA, Lascaratos G, Chau KY, Garway-Heath DF. Neuroprotection in Glaucoma: NAD+/NADH Redox State as a Potential Biomarker and Therapeutic Target. Cells. 2021 Jun 5;10(6):1402. doi: 10.3390/cells10061402.
Reference Type
BACKGROUND
Pirinen E, Auranen M, Khan NA, Brilhante V, Urho N, Pessia A, Hakkarainen A, Kuula J, Heinonen U, Schmidt MS, Haimilahti K, Piirila P, Lundbom N, Taskinen MR, Brenner C, Velagapudi V, Pietilainen KH, Suomalainen A. Niacin Cures Systemic NAD+ Deficiency and Improves Muscle Performance in Adult-Onset Mitochondrial Myopathy. Cell Metab. 2020 Jun 2;31(6):1078-1090.e5. doi: 10.1016/j.cmet.2020.04.008. Epub 2020 May 7.
Reference Type
BACKGROUND
Poljsak B, Kovac V, Milisav I. Current Uncertainties and Future Challenges Regarding NAD+ Boosting Strategies. Antioxidants (Basel). 2022 Aug 24;11(9):1637. doi: 10.3390/antiox11091637.
Reference Type
BACKGROUND
Ramsey KM, Yoshino J, Brace CS, Abrassart D, Kobayashi Y, Marcheva B, Hong HK, Chong JL, Buhr ED, Lee C, Takahashi JS, Imai S, Bass J. Circadian clock feedback cycle through NAMPT-mediated NAD+ biosynthesis. Science. 2009 May 1;324(5927):651-4. doi: 10.1126/science.1171641. Epub 2009 Mar 19.
Reference Type
BACKGROUND
Rajman L, Chwalek K, Sinclair DA. Therapeutic Potential of NAD-Boosting Molecules: The In Vivo Evidence. Cell Metab. 2018 Mar 6;27(3):529-547. doi: 10.1016/j.cmet.2018.02.011.
Reference Type
BACKGROUND
Shin JW, Sung KR, Lee J, Kwon J. Factors Associated With Visual Field Progression in Cirrus Optical Coherence Tomography-guided Progression Analysis: A Topographic Approach. J Glaucoma. 2017 Jun;26(6):555-560. doi: 10.1097/IJG.0000000000000680.
Reference Type
BACKGROUND
Sood A, Arora R. Mechanisms of flushing due to niacin and abolition of these effects. J Clin Hypertens (Greenwich). 2009 Nov;11(11):685-9. doi: 10.1111/j.1559-4572.2008.00050.x.
Reference Type
BACKGROUND
Tham YC, Li X, Wong TY, Quigley HA, Aung T, Cheng CY. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology. 2014 Nov;121(11):2081-90. doi: 10.1016/j.ophtha.2014.05.013. Epub 2014 Jun 26.
Reference Type
BACKGROUND
Trammell SA, Schmidt MS, Weidemann BJ, Redpath P, Jaksch F, Dellinger RW, Li Z, Abel ED, Migaud ME, Brenner C. Nicotinamide riboside is uniquely and orally bioavailable in mice and humans. Nat Commun. 2016 Oct 10;7:12948. doi: 10.1038/ncomms12948.
Reference Type
BACKGROUND
Tribble JR, Otmani A, Sun S, Ellis SA, Cimaglia G, Vohra R, Joe M, Lardner E, Venkataraman AP, Dominguez-Vicent A, Kokkali E, Rho S, Johannesson G, Burgess RW, Fuerst PG, Brautaset R, Kolko M, Morgan JE, Crowston JG, Votruba M, Williams PA. Nicotinamide provides neuroprotection in glaucoma by protecting against mitochondrial and metabolic dysfunction. Redox Biol. 2021 Jul;43:101988. doi: 10.1016/j.redox.2021.101988. Epub 2021 Apr 24.
Reference Type
BACKGROUND
Verdin E. NAD(+) in aging, metabolism, and neurodegeneration. Science. 2015 Dec 4;350(6265):1208-13. doi: 10.1126/science.aac4854.
Reference Type
BACKGROUND
Weinreb RN, Aung T, Medeiros FA. The pathophysiology and treatment of glaucoma: a review. JAMA. 2014 May 14;311(18):1901-11. doi: 10.1001/jama.2014.3192.
Reference Type
BACKGROUND
Williams PA, Harder JM, Foxworth NE, Cochran KE, Philip VM, Porciatti V, Smithies O, John SW. Vitamin B3 modulates mitochondrial vulnerability and prevents glaucoma in aged mice. Science. 2017 Feb 17;355(6326):756-760. doi: 10.1126/science.aal0092.
Reference Type
BACKGROUND
Xie N, Zhang L, Gao W, Huang C, Huber PE, Zhou X, Li C, Shen G, Zou B. NAD+ metabolism: pathophysiologic mechanisms and therapeutic potential. Signal Transduct Target Ther. 2020 Oct 7;5(1):227. doi: 10.1038/s41392-020-00311-7.
Reference Type
BACKGROUND
Zapata-Perez R, Wanders RJA, van Karnebeek CDM, Houtkooper RH. NAD+ homeostasis in human health and disease. EMBO Mol Med. 2021 Jul 7;13(7):e13943. doi: 10.15252/emmm.202113943. Epub 2021 May 27.
Reference Type
BACKGROUND
Zhang X, Zhang N, Chrenek MA, Girardot PE, Wang J, Sellers JT, Geisert EE, Brenner C, Nickerson JM, Boatright JH, Li Y. Systemic Treatment with Nicotinamide Riboside Is Protective in Two Mouse Models of Retinal Ganglion Cell Damage. Pharmaceutics. 2021 Jun 16;13(6):893. doi: 10.3390/pharmaceutics13060893.
Reference Type
BACKGROUND
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
H029
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Effect of Ginkgo Biloba Capsule on Visual Function of Primary Open-angle Glaucoma With Blood Stasis Syndrome
NCT04334564
UNKNOWN
NA
The Effects of an Antioxidant Formulation on Ocular Blood Flow
NCT01930487
COMPLETED
NA
Measurement of the Effect of Gingko Biloba Extract on Ocular and Nailfold Blood-flow in NTG
NCT03761992
UNKNOWN
NA
Relationship Between Eye Pressure and Ganglion Cell Function in Eyes Receiving Latanoprost Versus Placebo
NCT01042665
COMPLETED
Study of Glaucoma Treatment With Food Additives
NCT00196677
TERMINATED
PHASE1/PHASE2
Effect of Niacinamide Supplementation in Glaucoma
NCT07007260
COMPLETED
NA
Study of NT-501 Encapsulated Cell Therapy for Glaucoma Neuroprotection and Vision Restoration
NCT02862938
ACTIVE_NOT_RECRUITING
PHASE2
Efficacy and Tolerability of Preservative-free 0.0015% Tafluprost in Glaucoma Patients
NCT03104621
COMPLETED
PHASE4
Valuation of the Antioxidant and Neuroprotective Effects of CoQ10-MINIACTIVES® (COQUN® OS) in Patients Affected by Primary Open Angle Glaucoma
NCT04038034
UNKNOWN
NA
To Evaluate the Effect of Ginkgo Biloba Extract on Optic Nerve Head Perfusion Examined Using OCTA
NCT04846179
COMPLETED
PHASE4
NT-501 CNTF Implant for Glaucoma: Safety, Neuroprotection and Neuroenhancement
NCT01408472
COMPLETED
PHASE1
Effectiveness of a Procedure for Previously Failed Glaucoma Surgery
NCT00347789
COMPLETED
Optimal Non-invasive Brain Stimulation for Peripheral Vision
NCT04846140
RECRUITING
NA
Effects of Forskolin on Intraocular Pressure in Glaucomatous Patients Under Maximum Tolerated Medical Therapy
NCT00864578
WITHDRAWN
Acupuncture as Adjuvant Therapy for Glaucoma - Protocol for a Randomized Controlled Trial
NCT05753137
RECRUITING
NA
Effects of Forskolin on Intraocular Pressure in Glaucomatous Patients Under Treatment With Either Beta-blockers or Prostaglandins Eye Drops
NCT00863811
WITHDRAWN
Effects of Selective Laser Trabeculoplasty on Aqueous Humor Dynamics
NCT01342406
COMPLETED
Electrical Stimulation for the Treatment of Optic Neuropathies
NCT05626426
RECRUITING
NA
Evaluate the Efficacy and Safety of Glaucoma Implant in Primary Open Angle Glaucoma
NCT05892185
UNKNOWN
NA
Comparison of Topical Anesthesia and Analgosedation in Micropulse Transscleral Glaucoma Treatment
NCT04448080
COMPLETED
NA
Relationship Between Topiramate Use and Ocular Angle Status
NCT00153699
UNKNOWN
PHASE4
Regulation of Intraocular Pressure in Glaucoma Patients by Acupressure
NCT05898997
COMPLETED
NA
Impact of Oral Versatile Antioxidants on Glaucoma Progression
NCT01544192
COMPLETED
PHASE3
A Prospective Evaluation of Open-Angle Glaucoma Subjects on Two Topical Hypotensive Medications Treated With One Suprachoroidal Stent
NCT01252914
COMPLETED
PHASE4
A Study of the VISION5 Product in Patients With Glaucoma or Ocular Hypertension
NCT01943721
COMPLETED
PHASE1